Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

FARAFARA Cure FA

The Role of Frataxin in Doxorubicin Mediated Cardiac Hypertrophy

Am J Physiol Heart Circ Physiol. 2015 Jul 24:ajpheart.00182.2015. doi: 10.1152/ajpheart.00182.2015. [Epub ahead of print] Mouli S, Nanayakkara G, AlAlasmari A, Eldoumani H, Fu X, Berlin A, Lohani M, Nie B, Arnold R, Kavazis AN, Smith F, Beyers RJ, Denney T, Dhanasekaran M, Zhong J, Quindry JC, Amin RH
 

Doxorubicin (DOX) is a highly effective anti-neoplastic agent; however its cumulative dosing schedules are clinically limited by the development of cardiotoxicity. We also observed significant reduction in FXN expression in DOX treated animals and H9C2 cardiomyoblast cell lines resulting in increased mitochondrial iron accumulation and the ensuing ROS formation. This observation was paralleled in DOX treated H9C2 cells by a significant reduction in the mitochondrial bioenergetics as observed by the reduction of myocardial energy regulation. Surprisingly, similar results were observed in our FXN knock down (FXN-KD) stable cell lines constructed by lentiviral technology using shRNA. To better understand the cardioprotective role of FXN against DOX, we constructed frataxin over expressing cardiomyoblasts (FXN-OE) which displayed cardioprotection against mitochondrial iron accumulation, ROS formation and reduction of mitochondrial bioenergetics.

Read More:  The Role of Frataxin in Doxorubicin Mediated Cardiac Hypertrophy

 

 


About the Author

Jen Farmer

Jen Farmer

Executive Director

SHARE

FacebookTwitterLinkedinShare on Google+
Event G.jpg

 

Archived in
  Scientific News


 

 

Tagged in
FARA Scientific News